Press releases
2003
11-25-2003
curasan takes over existing business activities of Atrix in Germany
Exclusive distribution of Atridox® and Atrisorb®
Kleinostheim, 25 November 2003 - curasan AG has today concluded an agreement with Atrix Laboratories GmbH, a subsidiary of the US enterprise Atrix Laboratories, Inc. (Nasdaq: ATRX), covering the exclusive distribution of Atridox® and Atrisorb® in Germany ...10-30-2003
Approval by curasan's shareholders to sale of Pharmaceuticals unit results in higher profits
Kleinostheim, 31 Oct. 2003 At today's Extraordinary Meeting, curasan AG's shareholders approved the sale of the company's Pharmaceuticals business unit (also referred to as "AIEP" business unit) to DeltaSelect GmbH, a subsidiary of the exchange-listed German enterprise PlasmaSelect AG ...10-15-2003
curasan AG among the "Fast 50"
Deloitte & Touche honours Germany's high-growth companies
Kleinostheim/Düsseldorf, 15 Oct. 2003 - The selection of Germany's fastest growing technology companies has been made. curasan AG, an enterprise specialising in Regenerative Medicine, has been recognised as one of the most successful players within the marketplace ...09-19-2003
curasan AG - Sale of Pharmaceuticals Unit
Focus on Biomaterials and Regenerative Medicine
Kleinostheim, 19 September 2003- Effective from 1 November 2003, curasan AG (WKN 549 453) has sold its Pharmaceuticals business unit (generic AIEP pharmaceuticals) to DeltaSelect GmbH, a wholly-owned subsidiary of exchange-listed PlasmaSelect AG (WKN 547 180) ...07-21-2003
curasan AG: First six months prove successful
Revenues up by 24% - earnings performance improves substantially
Kleinostheim, July 21, 2003 - On the basis of preliminary figures, curasan AG (WKN: 549 453), a Prime Standard listed company specialising in regenerative medicine, has continued its positive trend of the two previous quarters by producing a solid performance in the second quarter of 2003. Revenues increased by 24% to EUR 8.8 million (previous year: EUR 7.2 million) ...06-16-2003
curasan announces US distribution of Cerasorb™VET
Distribution partnership finalised with New Generation Devices (NGD)
Kleinostheim, Germany, June 16, 2003 - Prime Standard listed curasan AG (WKN: 549 453), which specialises in regenerative medicine, has finalised a contract with the US firm New Generation Devices, Franklin Lakes, NJ/USA for distribution of Cerasorb™VET in the veterinary market ...05-07-2003
curasan AG: Q1/2003 - Best quarter ever
29% revenue growth and lowest loss since IPO
Kleinostheim, May 7, 2003 - According to preliminary figures for the first quarter of the fiscal year 2003, curasan AG (WKN: 549453) has been able to emulate its positive performance displayed at the end of 2002 ...02-05-2003
curasan rolls out Cerasorb Ortho in the US
Distribution partnerships with two US companies
Kleinostheim, February 5, 2003 - curasan AG (WKN 549 453), a German biomedical company listed within the Prime Standard segment, has signed agreements with the two US-based companies CryoLife Inc., Kennesaw/USA, and Spinal Concepts Inc., Austin/USA ...